These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1190 related articles for article (PubMed ID: 19874354)

  • 21. In vitro antifungal activity of Indian liposomal amphotericin B against clinical isolates of emerging species of yeast and moulds, and its comparison with amphotericin B deoxycholate, voriconazole, itraconazole and fluconazole.
    Rudramurthy SM; Jatana M; Singh R; Chakrabarti A
    Mycoses; 2013 Jan; 56(1):39-46. PubMed ID: 22519679
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Investigation of in vitro activities of fluconazole, itraconazole and voriconazole against clinical isolates of Blastoschizomyces capitatus (Geotrichum capitatum) by two different methods].
    Sancak B; Alp S; Hasçelik G; Arikan S
    Mikrobiyol Bul; 2009 Apr; 43(2):269-76. PubMed ID: 19621612
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro activity of voriconazole against selected fungi.
    McGinnis MR; Pasarell L; Sutton DA; Fothergill AW; Cooper CR; Rinaldi MG
    Med Mycol; 1998 Aug; 36(4):239-42. PubMed ID: 9776841
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative in vitro activity of voriconazole and itraconazole against fluconazole-susceptible and fluconazole-resistant clinical isolates of Candida species from Spain.
    Cuenca-Estrella M; Díaz-Guerra TM; Mellado E; Monzón A; Rodríguez-Tudela JL
    Eur J Clin Microbiol Infect Dis; 1999 Jun; 18(6):432-5. PubMed ID: 10442422
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [In vitro activity of voriconazole and three other antifungal agents against dermatophytes].
    Serrano-Martino Mdel C; Chávez-Caballero M; Valverde-Conde A; Claro RM; Pemán J; Martín-Mazuelos E
    Enferm Infecc Microbiol Clin; 2003 Nov; 21(9):484-7. PubMed ID: 14572380
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combinatorial effect of fluconazole, itraconazole, and terbinafine with different culture extracts of Candida parapsilosis and Trichophyton spp. against Trichophyton rubrum.
    Lemes TH; Nascentes JAS; Regasini LO; Siqueira JPZ; Maschio-Lima T; Pattini VC; Ribeiro MD; de Almeida BG; de Almeida MTG
    Int Microbiol; 2024 Jun; 27(3):899-905. PubMed ID: 37875749
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro susceptibility of dermatomycoses agents to six antifungal drugs and evaluation by fractional inhibitory concentration index of combined effects of amorolfine and itraconazole in dermatophytes.
    Tamura T; Asahara M; Yamamoto M; Yamaura M; Matsumura M; Goto K; Rezaei-Matehkolaei A; Mirhendi H; Makimura M; Makimura K
    Microbiol Immunol; 2014 Jan; 58(1):1-8. PubMed ID: 24215461
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the Vitek 2 yeast susceptibility system with CLSI microdilution for antifungal susceptibility testing of fluconazole and voriconazole against Candida spp., using new clinical breakpoints and epidemiological cutoff values.
    Pfaller MA; Diekema DJ; Procop GW; Rinaldi MG
    Diagn Microbiol Infect Dis; 2013 Sep; 77(1):37-40. PubMed ID: 23870164
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of in vitro antifungal activity of novel triazoles with available antifungal agents against dermatophyte species caused tinea pedis.
    Salehi Z; Fatahi N; Taran M; Izadi A; Badali H; Hashemi SJ; Rezaie S; Daie Ghazvini R; Ghaffari M; Aala F; Barac A; Khodavaisy S
    J Mycol Med; 2020 Jun; 30(2):100935. PubMed ID: 32139093
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic diversity and antifungal susceptibility of Fusarium isolates in onychomycosis.
    Rosa PD; Heidrich D; Corrêa C; Scroferneker ML; Vettorato G; Fuentefria AM; Goldani LZ
    Mycoses; 2017 Sep; 60(9):616-622. PubMed ID: 28657120
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro activities of voriconazole, fluconazole, itraconazole and amphotericin B against non Candida albicans yeast isolates.
    Swinne D; Watelle M; Nolard N
    Rev Iberoam Micol; 2005 Mar; 22(1):24-8. PubMed ID: 15813679
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro antifungal susceptibility testing of fungi in patients with onychomycosis.
    Abu El-Hamd M; Abd Elhameed MI; Shalaby MFM; Saleh R
    Dermatol Ther; 2020 May; 33(3):e13429. PubMed ID: 32304603
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro susceptibility of filamentous fungi to itraconazole, voriconazole and posaconazole by Clinical and Laboratory Standards Institute reference method and E-test.
    Kondori N; Svensson E; Mattsby-Baltzer I
    Mycoses; 2011 Sep; 54(5):e318-22. PubMed ID: 20557462
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro activities of terbinafine in combination with fluconazole, itraconazole, voriconazole, and posaconazole against clinical isolates of Candida glabrata with decreased susceptibility to azoles.
    Perea S; Gonzalez G; Fothergill AW; Sutton DA; Rinaldi MG
    J Clin Microbiol; 2002 May; 40(5):1831-3. PubMed ID: 11980970
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of in vitro antifungal activities of efinaconazole and currently available antifungal agents against a variety of pathogenic fungi associated with onychomycosis.
    Jo Siu WJ; Tatsumi Y; Senda H; Pillai R; Nakamura T; Sone D; Fothergill A
    Antimicrob Agents Chemother; 2013 Apr; 57(4):1610-6. PubMed ID: 23318803
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro evaluation of combination antifungal activity against Fusarium species isolated from ocular tissues of keratomycosis patients.
    Li L; Wang Z; Li R; Luo S; Sun X
    Am J Ophthalmol; 2008 Nov; 146(5):724-8. PubMed ID: 18707669
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [In vitro activity of fluconazole, voriconazole and posaconazole against Candida spp].
    Rubio Calvo MC; Gil J; Ramírez de Ocáriz I; Benito R; Rezusta A
    Rev Esp Quimioter; 2003 Jun; 16(2):227-32. PubMed ID: 12973462
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antifungal susceptibility of Cryptococcus neoformans isolates in HIV-infected patients to fluconazole, itraconazole and voriconazole in Spain: 1994-1996 and 1997-2005.
    Aller AI; Claro R; Castro C; Serrano C; Colom MF; Martín-Mazuelos E
    Chemotherapy; 2007; 53(4):300-5. PubMed ID: 17496416
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro activities of antifungal drugs against dermatophytes isolated in Tokat, Turkey.
    Yenişehirli G; Tunçoğlu E; Yenişehirli A; Bulut Y
    Int J Dermatol; 2013 Dec; 52(12):1557-60. PubMed ID: 24134487
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of visual 24-hour and spectrophotometric 48-hour MICs to CLSI reference microdilution MICs of fluconazole, itraconazole, posaconazole, and voriconazole for Candida spp.: a collaborative study.
    Espinel-Ingroff A; Barchiesi F; Cuenca-Estrella M; Fothergill A; Pfaller MA; Rinaldi M; Rodriguez-Tudela JL; Verweij PE
    J Clin Microbiol; 2005 Sep; 43(9):4535-40. PubMed ID: 16145103
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 60.